Quanterix (Quanterix) ROCE %

: -15.77% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Quanterix's annualized ROCE % for the quarter that ended in Dec. 2023 was -15.77%.

Quanterix ROCE % Historical Data

The historical data trend for Quanterix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-41.68

-16.56

-16.84

-16.68

-12.20

Quanterix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-12.61	-9.41	-9.59	-13.92	-15.77

Quanterix ROCE % Calculation

Quanterix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-48.164	/	( ( (434.199 - 30.958)	+	(425.011 - 38.457) )	/ 2 )
	=	-48.164	/	( (403.241	+	386.554)	/ 2 )
	=	-48.164	/	394.8975
	=	-12.20 %

Quanterix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-61.52	/	( ( (429.042 - 35.153)	+	(425.011 - 38.457) )	/ 2 )
	=	-61.52	/	( ( 393.889	+	386.554 )	/ 2 )
	=	-61.52	/	390.2215
	=	-15.77 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Quanterix (NAS:QTRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Quanterix ROCE % Related Terms

Thank you for viewing the detailed overview of Quanterix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quanterix (Quanterix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Middlesex Turnpike, Billerica, MA, USA, 01821

Website

https://www.quanterix.com

Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.

Executives

Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly	director	C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram	officer: Chief Financial Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser	director	561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle	officer: CFO and Treasurer	C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue	officer: President, Quanterix & Dx	C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka	director	2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
John J Fry	officer: General Counsel & Secretary	8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky	director, officer: EC, President & CEO	68 ELM STREET, HOPKINTON MA 01748
Karen Flynn	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy	officer: SVP R&D and CTO	C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon	officer: Sr VP, Stgc Mrktg & Assay Tech	113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421